Kerala ayurveda Limited has announced the closure of its trading window for designated persons and their immediate relatives, effective from March 31, 2026. The closure will remain in effect until 48 hours after the company announces its audited financial results for the quarter and year ending March 31, 2026.

Regulatory Compliance

The trading window closure is implemented in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, including any amendments. The measure also aligns with the company's internal "Code of Conduct for Regulating, Monitoring, Preventing and Reporting of Trading in Securities by Insiders and Designated Persons and Immediate Relatives of Designated Persons."

Additional Regulatory Measures

Pursuant to SEBI circular no. SEBI/HO/ISD/ISD-PoD-2/P/CIR/2025/55 dated April 21, 2025, the PAN of designated persons and their immediate relatives will be frozen by Central Depository Services (India) Limited during the window closure period. This measure serves as an additional safeguard to prevent insider trading during the sensitive period leading up to the financial results announcement.

Board Meeting Schedule

The company has indicated that the date of the Board of Directors meeting to approve the financial results for the quarter and year ending March 31, 2026, will be communicated separately in due course. The trading window will reopen 48 hours after the official announcement of these audited financial results.

The notification was signed by George K T, Chief Financial Officer and Compliance Officer of Kerala Ayurveda Limited, on March 26, 2026. The company maintains its registered office in Ernakulam, Kerala, and corporate office in Bengaluru, Karnataka.

Kerala ayurveda Limited's Board of Directors has successfully concluded its meeting held on March 25, 2026, and approved the issuance of Series A Non-Convertible Debentures worth Rs. 40 crores. The meeting, which was previously scheduled in accordance with Regulation 29(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, commenced at 11:00 AM and concluded at 12:10 PM.

Board Approval Details

The board has approved the issuance of 4,000 Series "A" unlisted, secured and redeemable Non-Convertible Debentures on a private placement basis. Each debenture carries a face value of Rs. 1,00,000 and will be issued at par, aggregating to Rs. 40,00,00,000.

Financial Structure and Terms

The debentures will carry an interest rate of 12% per annum on reducing balance basis, with quarterly interest payments. The repayment structure includes a moratorium period of 24 months followed by 32 quarterly instalments for principal repayment.

Security and Compliance

The NCDs will be secured by a first charge on the company's industrial property, including factory land, building, plant and machinery located at Survey No. 264/1, 264/26, 264/27, Near St. Francis Assisi Church, Airport Road, Nedumbassery, Village Chengamanad, Taluka Aluva, District Ernakulam, Kerala. The borrowing falls within the limits approved by shareholders on August 22, 2025, under Section 180(1)(c) of the Companies Act, 2013.

Corporate Communication

George K T, Chief Financial Officer and Designated Officer for filing, communicated the outcome to the Bombay Stock Exchange through an official disclosure dated March 25, 2026. The information has been made available on the company's website at www.keralaayurveda.biz for stakeholder access. Kerala Ayurveda Limited operates as an ISO 9001:2015 certified company with its registered office in Athani, Nedumbassery, Ernakulam, Kerala, and corporate office in Bengaluru, Karnataka.